PROJECT

Projects

Environmental & Social Review Summary

Project Number

43417

Company Name

LABORATORIOS BUSSIE S A

Date ESRS Disclosed

Sep 25, 2020

Country

Colombia

Region

Latin America and the Caribbean

Last Updated Date

Nov 6, 2020

Environmental Category

B - Limited

Status

Hold

Sector

other

Industry

Health, Education and Life Sciences

Department

Regional Industry MAS LAC & EUR

Project Description

 Founded in 1941, Laboratorios Sanfer (“Sanfer”) is the second largest domestic pharmaceutical company in Mexico and amongst the top 8 largest in Latin America. Laboratorios Bussie, S.A. (“Bussie”) and Laboratorio International de Colombia, S.A.S. (“Labinco”) are fully owned subsidiaries of Sanfer and were acquired in 2008 and 2015, respectively. Bussie and Labinco (hereafter referred to as “Sanfer Colombia”) commercialize a wide portfolio of prescription and over-the-counter (OTC) drugs (e.g. pulmonology, ophthalmology, gastrointestinal, cardiovascular, psychoactive, antiparasitic, antibiotics, and veterinary drugs). With exception of veterinary drugs which are produced by three third-party contract manufacturers, the majority of drugs are produced in Bussie’s and Labinco’s manufacturing plants located in Bogota, Colombia. IFC propose financing a $11.5 million for the construction of a new manufacturing plant for finished dosage forms, which will replace the existing operations, to satisfy the new and more stringent regulatory requirements from the National Institute for Drugs and Food Surveillance (INVIMA). The new plant will be located in an industrial area in the city of Bogota, a few blocks from the existing plants https://goo.gl/maps/jDJQN6VqzQBxejQ49. Administrative offices and the quality control laboratory will remain in separate existing locations.

                                                  

Overview of IFC's Scope of Review

 The E&S review of the proposed investment was based on document review and video conferences with company’s staff from July 1st to July 17th, 2020. No field visit was conducted due to the COVID-19 travel restrictions. A virtual site visit took place to examine the storage areas of hazardous materials and hazardous waste, boilers, generators, dust collection systems, quality control laboratory, and to review the safety features of pharmaceutical equipment. A supplemental field visit will be conducted once travel restrictions are lifted and the ESRS and ESAP as disclosed will be updated in the event of material additional findings. The review included interviews with personnel responsible for operations, maintenance, human resources, occupational health and safety (OHS), and environment.  

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan